DMD Warrior

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Powered by Hostinger

Latest Articles

GEN6050X Exon 50 Skipping Base Editing Drug: One-Year Results Show Encouraging Progress for Duchenne Muscular Dystrophy

Press Releases July 25, 2026 0

The GEN6050X exon 50 skipping base editing drug, developed...

Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027

Research July 24, 2026 0

For families affected by Duchenne muscular dystrophy (DMD), every...

7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026

Editorials July 22, 2026 6

The landscape of Duchenne muscular dystrophy (DMD) research is...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Therapies December 26, 2024 4

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Editorials April 10, 2026 9

The landscape of potential new gene therapies for Duchenne...

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control

Editorials April 6, 2026 2

The duchenne muscular dystrophy treatment cost has become one...

Duchenne MD

Genetic

Care Guidelines

Health Guidelines

Latest Posts

GEN6050X Exon 50 Skipping Base Editing Drug: One-Year Results Show Encouraging Progress for Duchenne Muscular Dystrophy

Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027

7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026

Latest Posts

GEN6050X Exon 50 Skipping Base Editing Drug: One-Year Results Show Encouraging Progress for Duchenne Muscular Dystrophy

Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027

7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen, an Exon 51 Skipping Therapy for Duchenne Muscular Dystrophy (DMD)

Don't Miss

Dystrophin Gene in Duchenne Muscular Dystrophy: Function, Mutations & Treatments

Constipation in Duchenne Muscular Dystrophy: Causes, Symptoms & Treatment

Calcium in Duchenne Muscular Dystrophy: Mechanisms, Risks, and Treatment Insights

Why CK, AST, and ALT Data Matter More Than Videos in Duchenne Gene Therapy

Does My Child Have Duchenne Muscular Dystrophy (DMD)?

About us

Latest Articles

GEN6050X Exon 50 Skipping Base Editing Drug: One-Year Results Show Encouraging Progress for Duchenne Muscular Dystrophy

Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027

7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026

Most Popular

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control